Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

NextCure

DB:2US
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2US
DB
$995M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • NextCure has significant price volatility in the past 3 months.
2US Share Price and Events
7 Day Returns
-3.2%
DB:2US
2.2%
DE Biotechs
7.2%
DE Market
1 Year Returns
-
DB:2US
-9%
DE Biotechs
-14.3%
DE Market
2US Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NextCure (2US) -3.2% -13.6% -40.6% - - -
DE Biotechs 2.2% 0.4% -23.6% -9% 16.2% -12.2%
DE Market 7.2% -3.5% -22% -14.3% -19.9% -25.7%
1 Year Return vs Industry and Market
  • No trading data on 2US.
  • No trading data on 2US.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is NextCure undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for NextCure. This is due to cash flow or dividend data being unavailable. The share price is €30.6.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NextCure's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NextCure's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2US PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.15
NasdaqGS:NXTC Share Price ** NasdaqGS (2020-04-08) in USD $36.18
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 42.02x
Germany Market PE Ratio Median Figure of 403 Publicly-Listed Companies 17.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NextCure.

DB:2US PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:NXTC Share Price ÷ EPS (both in USD)

= 36.18 ÷ -2.15

-16.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NextCure is loss making, we can't compare its value to the Europe Biotechs industry average.
  • NextCure is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does NextCure's expected growth come at a high price?
Raw Data
DB:2US PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -16.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-25.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NextCure, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NextCure's assets?
Raw Data
DB:2US PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $11.69
NasdaqGS:NXTC Share Price * NasdaqGS (2020-04-08) in USD $36.18
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.4x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.5x
DB:2US PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:NXTC Share Price ÷ Book Value per Share (both in USD)

= 36.18 ÷ 11.69

3.09x

* Primary Listing of NextCure.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NextCure is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess NextCure's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NextCure has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NextCure expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-25.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NextCure expected to grow at an attractive rate?
  • Unable to compare NextCure's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare NextCure's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • NextCure's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2US Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2US Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -25.2%
DB:2US Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 71.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 37.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2US Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2US Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 521 -99 -142 4
2023-12-31 171 -126 -135 3
2022-12-31 5 -96 -89 3
2021-12-31 4 -97 -69 5
2020-12-31 8 -79 -57 5
2020-04-09
DB:2US Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 6 -36 -34
2019-09-30 4 -3 -30
2019-06-30 3 0 -27
2019-03-31 1 6 -24
2018-12-31 8 -23
2017-12-31 -13 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NextCure is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • NextCure's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2US Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from NextCure Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2US Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -4.41 -3.29 -5.74 3.00
2023-12-31 -4.48 -3.72 -5.13 3.00
2022-12-31 -3.12 -2.47 -4.00 4.00
2021-12-31 -2.47 -1.81 -3.17 7.00
2020-12-31 -2.15 -1.70 -3.44 6.00
2020-04-09
DB:2US Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.15
2019-09-30 -3.03
2019-06-30 -6.09
2019-03-31 -17.46
2018-12-31 -16.64
2017-12-31 -11.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NextCure will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess NextCure's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NextCure has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NextCure performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NextCure's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NextCure does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare NextCure's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NextCure's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NextCure's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NextCure Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2US Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 6.35 -33.74 9.61
2019-09-30 4.34 -29.67 7.81 20.21
2019-06-30 2.76 -26.95 6.12 19.79
2019-03-31 1.36 -23.96 4.27 22.09
2018-12-31 -22.80 3.41
2017-12-31 -15.47 2.60 12.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NextCure has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NextCure has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NextCure improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NextCure's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NextCure has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NextCure's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NextCure's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NextCure is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NextCure's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NextCure's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 68x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NextCure Company Filings, last reported 3 months ago.

DB:2US Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 321.48 5.00 334.61
2019-09-30 170.65 5.00 184.08
2019-06-30 178.60 5.00 192.69
2019-03-31 109.51 5.00 125.55
2018-12-31 115.28 0.46 135.17
2017-12-31 15.59 0.86 8.43
  • NextCure's level of debt (1.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if NextCure's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NextCure has sufficient cash runway for more than 3 years based on current free cash flow.
  • NextCure has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 27.3% each year.
X
Financial health checks
We assess NextCure's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NextCure has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NextCure's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NextCure dividends.
If you bought €2,000 of NextCure shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NextCure's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NextCure's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2US Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2US Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NextCure has not reported any payouts.
  • Unable to verify if NextCure's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NextCure's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NextCure has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NextCure's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NextCure afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NextCure has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NextCure's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Richman
COMPENSATION $2,501,597
AGE 58
TENURE AS CEO 4.5 years
CEO Bio

Mr. Michael S. Richman, MSBA, Co-founded NextCure, Inc. since 2015 and has been its Chief Executive Officer, President & Director since October 2015. Mr. Richman served as the Chief Executive Officer and President of Amplimmune, Inc. from 2008 to 2015. He served as an Executive Vice President and Chief Operating Officer of MacroGenics, Inc. from April 2002 to May 2007. He joined MacroGenics, Inc. in 2002. He served as President and Chief Operating Officer of Amplimmune from May 2007 to June 2008. He has almost 30 years' experience working in pharmaceutical research and business development. He helped found Amplimmune, a spinout from Johns Hopkins University and has since overseen its acquisition by MedImmune, the global biologics research and development arm of AstraZeneca, as a part of their global commitment to immunotherapy and developing novel medicines for patients. He served as President and Chief Executive Officer of AstraZeneca. Mr. Richman has held positions in companies including Chiron Corporation (now Novartis) and MacroGenics. He was employed at Eliance Biotechnology, Inc. He served as the Senior Vice President of Corporate Development Administration at Astra Zeneca (formerly, MedImmune, Inc. and MedImmune, LLC) from December 2000 to March 2002 and as its Vice President of Business Development from November 1996 to December 2000. While at MedImmune, Mr. Richman was responsible for all business development, licensing, intellectual property, legal affairs, project management and strategic planning functions and drove many significant transactions during that period. From 1985 to 1996, he served in various senior positions at Novartis and served as Director of corporate business development. He served as Manager of Business Development at Chiron Corporation from 1990 to 1992 and Manager of Intellectual Property from 1988 to 1990. He served as the Chairman of GenVec, Inc. since October 20, 2016 until June 16, 2017 and served as its Independent Director since April 22, 2015 until June 16, 2017. He has served on the supervisory board of Pieris GmbH since October 2014. He has been Independent Director of Pieris Pharmaceuticals, Inc. (formerly, Marika Inc) since December 17, 2014. He has been an Independent Director of Opexa Therapeutics, Inc. since June 16, 2006. He has been a Director of Madison Vaccines, Inc. since May 14, 2014 and PharmaFrontiers Corp. since June 16, 2006. He serves as a Director of Amplimmune, Inc. He served as Director of Cougar Biotechnology, Inc. from June 8, 2006 to July 2009. He served as a Director of Acer Therapeutics Inc. Mr. Richman holds a MSBA degree in International Business from San Francisco State University with a concentration in International Business and a B.S. degree in Genetics and Molecular Biology from the University of California at Davis.

CEO Compensation
  • Insufficient data for Michael to compare compensation growth.
  • Michael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the NextCure management team in years:

1.7
Average Tenure
55.5
Average Age
  • The average tenure for the NextCure management team is less than 2 years, this suggests a new team.
Management Team

Michael Richman

TITLE
Co-Founder
COMPENSATION
$3M
AGE
58
TENURE
4.5 yrs

Steve Cobourn

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
56
TENURE
2.3 yrs

Sol Langermann

TITLE
Chief Scientific Officer
COMPENSATION
$882K
AGE
60
TENURE
1.3 yrs

Lieping Chen

TITLE
Co-Founder & Chairman of Scientific Advisory Board
AGE
62
TENURE
5.3 yrs

Tim Mayer

TITLE
Chief Operating Officer
AGE
55
TENURE
0.5 yrs

Kevin Heller

TITLE
Chief Medical Officer
AGE
48
TENURE
2 yrs

Linda Liu

TITLE
Senior Vice President of Research
AGE
53
TENURE
1.3 yrs

James Bingham

TITLE
Chief Development Officer
AGE
53
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the NextCure board of directors in years:

4.3
Average Tenure
58.5
Average Age
  • The tenure for the NextCure board of directors is about average.
Board of Directors

David Kabakoff

TITLE
Independent Chairman of the Board
COMPENSATION
$183K
AGE
71
TENURE
4.3 yrs

Michael Richman

TITLE
Co-Founder
COMPENSATION
$3M
AGE
58
TENURE
4.5 yrs

Lieping Chen

TITLE
Co-Founder & Chairman of Scientific Advisory Board
AGE
62

Elaine Jones

TITLE
Independent Director
AGE
64
TENURE
4.3 yrs

Stephen Webster

TITLE
Independent Director
AGE
58
TENURE
1 yrs

Chau Khuong

TITLE
Independent Director
AGE
43
TENURE
4.3 yrs

Judith Li

TITLE
Independent Director
AGE
35
TENURE
4.3 yrs

Briggs Morrison

TITLE
Independent Director
AGE
59
TENURE
1 yrs

Stella Xu

TITLE
Independent Director
AGE
49
TENURE
1.4 yrs

Mario Sznol

TITLE
Member of Scientific Advisory Board
AGE
61
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Nov 19 Buy Sofinnova Investment, Inc. Company 15. Nov 19 15. Nov 19 150,000 €33.27 €4,989,915
15. May 19 Buy Sofinnova Investment, Inc. Company 13. May 19 13. May 19 400,000 €13.35 €5,341,800
13. May 19 Buy OrbiMed Advisors LLC Company 13. May 19 13. May 19 350,000 €13.35 €4,674,075
13. May 19 Buy Quan Capital Company 13. May 19 13. May 19 125,000 €13.35 €1,669,313
13. May 19 Buy Canaan Partners Company 13. May 19 13. May 19 50,000 €13.35 €667,725
X
Management checks
We assess NextCure's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NextCure has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.

Details
Name: NextCure, Inc.
2US
Exchange: DB
Founded: 2015
$915,272,428
27,509,510
Website: http://www.nextcure.com
Address: NextCure, Inc.
9000 Virginia Manor Road,
Suite 200,
Beltsville,
Maryland, 20705,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS NXTC Common Stock Nasdaq Global Select US USD 09. May 2019
DB 2US Common Stock Deutsche Boerse AG DE EUR 09. May 2019
MUN 2US Common Stock Boerse Muenchen DE EUR 09. May 2019
Number of employees
Current staff
Staff numbers
69
NextCure employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 03:49
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/24
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.